83 related articles for article (PubMed ID: 26602021)
1. Hope and hype surrounding circulating microRNA as potential next generation AML biomarkers.
Abdelhamed S; Kurre P
Leuk Res; 2015 Dec; 39(12):1309-11. PubMed ID: 26602021
[No Abstract] [Full Text] [Related]
2. The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
Koutova L; Sterbova M; Pazourkova E; Pospisilova S; Svobodova I; Horinek A; Lysak D; Korabecna M
Leuk Res; 2015 Dec; 39(12):1389-95. PubMed ID: 26340914
[TBL] [Abstract][Full Text] [Related]
3. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.
Zhi Y; Xie X; Wang R; Wang B; Gu W; Ling Y; Dong W; Zhi F; Liu Y
Int J Hematol; 2015 Sep; 102(3):296-303. PubMed ID: 26134365
[TBL] [Abstract][Full Text] [Related]
4. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
[TBL] [Abstract][Full Text] [Related]
5. Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy.
Medina D; David K; Lin Y; Schaar D; Patel V; Gharibo M; Bannerji R; Walton K; Aisner J; Rabson AB; Strair R
Leuk Lymphoma; 2017 May; 58(5):1227-1230. PubMed ID: 27659510
[No Abstract] [Full Text] [Related]
6. Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.
Hornick NI; Huan J; Doron B; Goloviznina NA; Lapidus J; Chang BH; Kurre P
Sci Rep; 2015 Jun; 5():11295. PubMed ID: 26067326
[TBL] [Abstract][Full Text] [Related]
7. Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy.
Spinello I; Quaranta MT; Paolillo R; Pelosi E; Cerio AM; Saulle E; Lo Coco F; Testa U; Labbaye C
Haematologica; 2015 Sep; 100(9):1160-71. PubMed ID: 26045293
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
[TBL] [Abstract][Full Text] [Related]
9. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
10. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
11. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract][Full Text] [Related]
13. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of microRNAs in chronic and acute human leukemia.
Yeh CH; Moles R; Nicot C
Mol Cancer; 2016 May; 15(1):37. PubMed ID: 27179712
[TBL] [Abstract][Full Text] [Related]
16. Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.
Huang Y; Zou Y; Lin L; Ma X; Chen H
Cancer Biomark; 2018; 22(4):799-805. PubMed ID: 29945348
[TBL] [Abstract][Full Text] [Related]
17. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
20. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
